The association between placebo arm inclusion and adverse event rates in antidepressant randomized controlled trials: An examination of the Nocebo Effect-Reference-Cited by-同舟云学术

The association between placebo arm inclusion and adverse event rates in antidepressant randomized controlled trials: An examination of the Nocebo Effect

Published:2021-02 Issue: Volume:280 Page:140-147
ISSN:0165-0327
Container-title:Journal of Affective Disorders
language:en
Short-container-title:Journal of Affective Disorders

Author:

Cheung Christian P.,Thiyagarajah Mathura T.,Abraha Haben Y.,Liu Celina S.,Lanctôt Krista L.,Kiss Alex J.,Saleem Mahwesh,Juda Ari,Levitt Anthony J.,Schaffer Ayal,Cheung Amy H.,Sinyor Mark

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology

Reference104 articles.

1. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder;Amsterdam;J. Clin. Psychiatry,2003

2. Nonspecific medication side effects and the nocebo phenomenon;Barsky;JAMA,2002

3. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study;Behnke;J. Clin. Psychopharmacol.,2003

4. Mirtazapine compared with paroxetine in major depression;Benkert;J. Clin. Psychiatry,2000

5. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder;Bielski;J. Clin. Psychiatry,2004

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nocebo effects and influencing factors in the randomized clinical trials of chronic constipation: A systematic review and meta‐analysis;Neurogastroenterology & Motility;2023-11-07

2. The Use of Authorized Concealment to Minimize Nocebo Side Effects: A Survey of US Public Attitudes;Psychotherapy and Psychosomatics;2023

3. A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults;Therapeutic Advances in Psychopharmacology;2023-01

4. Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder;The Journal of Clinical Psychiatry;2022-05-30

5. MicroRNAs as Critical Biomarkers of Major Depressive Disorder: A Comprehensive Perspective;Biomedicines;2021-11-10